Upstream Bio's (NASDAQ:UPB - Get Free Report) lock-up period will end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. After the end of Upstream Bio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Upstream Bio Price Performance
Upstream Bio stock traded down $0.20 on Friday, hitting $6.10. The company's stock had a trading volume of 212,237 shares, compared to its average volume of 324,380. Upstream Bio has a one year low of $5.59 and a one year high of $29.46. The firm has a fifty day simple moving average of $8.18.
Institutional Trading of Upstream Bio
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets bought a new position in Upstream Bio during the fourth quarter worth about $25,000. US Bancorp DE acquired a new position in shares of Upstream Bio in the 4th quarter worth approximately $27,000. Legal & General Group Plc bought a new position in shares of Upstream Bio during the 4th quarter worth approximately $28,000. Summit Investment Advisors Inc. acquired a new stake in Upstream Bio in the 4th quarter valued at $30,000. Finally, Tower Research Capital LLC TRC bought a new stake in Upstream Bio in the fourth quarter valued at $47,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
